Facebook
Twitter
LinkedIn
Forward
New Eye-Opening Approaches to the Treatment of Blepharoptosis (Archived CME/CE Webcast)
This educational activity has expired. You will not be able to claim credit for this activity.
Activity Description and Purpose
Blepharoptosis is drooping of the upper eyelid margin with the eye in primary gaze that has either a congenital or acquired etiology. It is estimated that 12% of adults aged > 50 years have some form of blepharoptosis. Surgery in the form of blepharoplasty has been the standard of care, but with it comes limitations due to skill, cost, and complications. Surgery is also limited to those with medical degrees—typically ophthalmologists and ocular plastic surgeons—which leaves optometrists outside of the realm of being able to provide treatment to their patients. A first-in-class, ophthalmic topical solution has recently been approved to treat acquired forms of adult blepharoptosis and has the potential to change practice behavior and provide a nonsurgical approach to improve the outcomes of patients with acquired blepharoptosis.
Target Audience
This educational activity is intended for ophthalmologists and optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Review the pathophysiology of blepharoptosis
- Review clinical data on the medical treatments for blepharoptosis
- Demonstrate selection of potential candidates for the medical treatments for blepharoptosis on the basis of clinical trial data
 Shane Kannarr, OD Kannarr Eye Care Pittsburg, Kansas |
 Steven M. Silverstein, MD, FACS Clinical Professor of Ophthalmology Kansas City University of Medicine and Biosciences Cataract and Refractive Surgeon Silverstein Eye Centers Kansas City, Missouri |
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Faculty
Shane Kannarr, OD, is a consultant for Alcon, Allergan, Essilor, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, Osmotica Pharmaceuticals plc, and Sight Sciences; is a contracted researcher for Alcon, Allergan, Bausch & Lomb Incorporated, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, and Osmotica Pharmaceuticals plc; and is on the speakers bureau for Allergan and Johnson & Johnson Vision Care, Inc.
Steven M. Silverstein, MD, is a consultant for Ace Vision Group, Inc, Alcon, APX Ophthalmology Ltd, Bausch & Lomb Incorporated, Beaver-Visitec International, Bio-Tissue, Bruder Healthcare, Diopsys, Inc, EyePoint Pharmaceuticals, Glaukos Corporation, Ocular Therapeutix, Inc, Omeros Corporation, Osmotica Pharmaceuticals plc, Sun Pharmaceutical Industries, Inc, and Tarsius Pharma Ltd; and is on the speakers bureau for Alcon, Bausch & Lomb Incorporated, Beaver-Visitec International, Bio-Tissue, Diopsys, Inc, Dompé US, Inc, EyePoint Pharmaceuticals, Mallinckrodt, Ocular Therapeutix, Inc, Omeros Corporation, Osmotica Pharmaceuticals plc, and Sun Pharmaceutical Industries, Inc.
Peer Reviewer
Angie E. Wen, MD, has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
COPE approved for 1.0 CE credit for optometrists.
COPE Course ID: 69548-AS (Interactive Distance Learning Course)
COPE Course Category: Treatment & Management of Ocular Disease: Anterior Segment (AS)
Administrator: 
Sponsored by: 
Disclosure of Commercial Support
This continuing medical education activity is supported through an unrestricted educational grant from RVL Pharmaceuticals, Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry, MedEdicus LLC, or RVL Pharmaceuticals, Inc.
This CME/CE activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 223